Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
190.60
-2.37 (-1.23%)
Official Closing Price
Updated: 7:00 PM EST, Feb 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
3 Fabulous Dividend Stocks to Buy in February
Today 14:30 EST
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Today 8:04 EST
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
Via
StockStory
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Today 8:02 EST
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.
Via
StockStory
3 Dividend Stocks to Double Up on Right Now
Today 5:43 EST
Via
The Motley Fool
These 2 Dividend Stocks Are Absolute Bargains Right Now
February 08, 2025
Via
The Motley Fool
Looking At AbbVie's Recent Unusual Options Activity
February 03, 2025
Via
Benzinga
Why AbbVie Stock Is Jumping Today
January 31, 2025
Via
The Motley Fool
3 Top AI-Powered Biotech Stocks to Buy in February
February 06, 2025
Via
The Motley Fool
Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase
February 05, 2025
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.” He added, “I can't believe the stock dropped so much.”
Via
Benzinga
Exploring the top movers within the S&P500 index during today's session.
February 03, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.
Via
Chartmill
Can Biotech Stocks Survive The Precarious Macro?
February 03, 2025
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.
Via
Talk Markets
Topics
Stocks / Equities
World Trade
Exposures
Tariff
Top S&P500 movers in Monday's session
February 03, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Via
Chartmill
Nike To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
February 03, 2025
Via
Benzinga
What You Missed On Friday
February 02, 2025
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Topics
Stocks / Equities
U.S. Equity Rally Reverses As White House Confirms Imminent Tariffs, Shifting Focus To Fed Policy
February 02, 2025
Under the surface, markets remain preoccupied with the potential impact of tariffs, shifting inflation expectations, and the Federal Reserve’s policy trajectory.
Via
Talk Markets
Topics
Commodities
Economy
Futures
Exposures
Interest Rates
Tariff
Small- To Mid-Cap Biotech Trades Poised For Gains
February 01, 2025
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.
February 01, 2025
Via
The Motley Fool
What's going on in today's session: S&P500 movers
January 31, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via
Chartmill
AbbVie (NYSE:ABBV) Posts Better-Than-Expected Sales In Q4, Stock Soars
January 31, 2025
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share...
Via
StockStory
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
January 31, 2025
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.
Via
Benzinga
AbbVie (ABBV) Q4 2024 Earnings Call Transcript
January 31, 2025
ABBV earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Top S&P500 movers in Friday's session
January 31, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday?
January 31, 2025
Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
AbbVie Investors Trigger Trend-Following Signal: Time to Load Up
January 31, 2025
AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens
January 31, 2025
The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.
Via
Stocktwits
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday
January 31, 2025
Via
Benzinga
AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline
January 31, 2025
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs.
Via
Benzinga
Topics
Earnings
Exposures
Financial
5 Top Stocks to Buy in February 2025
January 31, 2025
All of them have great upside.
Via
The Motley Fool
Friday's pre-market session: top gainers and losers in the S&P500 index
January 31, 2025
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.
Via
Chartmill
AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate
January 31, 2025
The company now expects Skyrizi and Rinvoq to bring in $31 billion in combined sales in 2027.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.